Among these, AZD-4573 is a highly selective CDK9 inhibitor that induces cancer cell apoptosis and cell death via MCL-1 depletion, thus showing promising preclinical in vivo efficacy, both as a monotherapy and in combination with Venetoclax, in hematologic cancer models [31]. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.